Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
British Journal of Pharmacology|October 22, 2025
History, pharmacology and therapeutic mechanisms of 3,4-methylenedioxymethamphetamine (MDMA)Austen B Casey, Boris D Heifets
ACS Chemical Neuroscience|April 4, 2017
Classics in Chemical Neuroscience: AripiprazoleAusten B Casey, Clinton E Canal
Biochemical Pharmacology|April 5, 2022
"Selective" serotonin 5-HT2A receptor antagonistsAusten B Casey, Meng Cui, Raymond G Booth, et al.
British Journal of Pharmacology|November 27, 2021
A new class of 5-HT2A /5-HT2C receptor inverse agonists: Synthesis, molecular modeling, in vitro and in vivo pharmacology of novel 2-aminotetralinsAusten B Casey, Munmun Mukherjee, Ryan P McGlynn, et al.
Nature Communications|January 21, 2026
No evidence of immediate or persistent analgesic effect from a single dose of psilocybin in three mouse models of painNicholas S Gregory, Tyler E Girard, Akila Ram, et al.
Biorxiv : the Preprint Server for Biology|July 17, 2025
Psilocybin has no immediate or persistent analgesic effect in acute and chronic mouse pain modelsNicholas S Gregory, Tyler E Girard, Akila Ram, et al.
Biorxiv : the Preprint Server for Biology|March 18, 2024
Opioid receptor expressing neurons of the central amygdala gate behavioral effects of ketamine in miceMatthew B Pomrenze, Sam Vaillancourt, Pierre Llorach, et al.
Bioorganic & Medicinal Chemistry|December 29, 2019
Synthesis of novel 5-substituted-2-aminotetralin analogs: 5-HT1A and 5-HT7 G protein-coupled receptor affinity, 3D-QSAR and molecular modelingCharles K Perry, Austen B Casey, Daniel E Felsing, et al.
Biological Psychiatry|May 7, 2025
Ketamine evokes acute behavioral effects via μ-opioid receptor expressing neurons of the central amygdalaMatthew B Pomrenze, Sam Vaillancourt, Pierre Llorach, et al.
Pageof 2